Incyte INCY
Incyte is the 370th largest S&P 500 company by market cap, worth $23.5 billion. 9 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 12 other officers are on file. At 30 Jun 2026, Baker Bros. Advisors was its largest institutional holder, with 15.4% of the company.
- CEO
- William Meury
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- Wilmington, Delaware
- Founded
- 1991
- More
- Wikipedia
- Market cap
- $23.5B
- 370th largest, 23 Oct 2026 close
- Price to sales
- 4.6
- Market cap over revenue
- Market cap per employee
- $8.2M
- Market cap over employees
- Connections
- 2
- S&P 500 companies sharing a director or officer
Largest institutional holders
Each fund group's share of Incyte. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Board and officers
2 people here also hold roles at other S&P 500 companies.
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (9) | |
| William MeuryChief Executive Officer | |
| Felix BakerDirector | |
| Julian BakerDirector | |
| Jean Jacques BienaimeDirector | |
| Otis W. BrawleyDirectorAlso at Agilent Technologies | |
| Paul J. ClancyDirector | |
| Jacqualyn A. FouseDirector | |
| Edmund HarriganDirector | |
| Katherine A. HighDirector | |
| Officers (12) | |
| Suketu UpadhyayEVP & Chief Financial OfficerAlso at Vertex PharmaceuticalsLast filed 6 May 2026 | |
| Ramitpal K. BasiEVP, Human ResourcesLast filed 27 Aug 2026 | |
| Pablo J. CagnoniPresident, Global Head of R&DLast filed 17 Sep 2026 | |
| David H. GardnerEVP, Chief Strategy OfficerLast filed 24 Sep 2026 | |
| Lee HeesonEVP, Head of Incyte IntlLast filed 27 Jul 2026 | |
| Richard A. HoffmanEVP & General CounselLast filed 20 Jul 2026 | |
| Mohamed Khairie IssaEVP, Head of U.S. CommercialLast filed 20 Jul 2026 | |
| Patrick A. MayesEVP & Chief Scientific OfficerLast filed 7 Aug 2026 | |
| Michael James MorrisseyEVP, Head of Tech. OperationsLast filed 27 Jul 2026 | |
| Steven H. SteinCMO & Head of Late-Stage DevLast filed 20 Jul 2026 | |
| Thomas TrayPrincipal Accounting OfficerLast filed 20 Jul 2026 | |
| Matteo TrottaEVP, GM, Dermatology USLast filed 26 Mar 2026 | |
Companies that share people with Incyte
Each person's title here, then at the other company.
- Agilent Technologies A
- Otis W. Brawley: Director here, Director there
- Vertex Pharmaceuticals VRTX
- Suketu Upadhyay: EVP & Chief Financial Officer here, Director there
Incyte's market cap since December 2008
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 23 Oct 2026
| Week ending | Market cap |
|---|---|
| 23 Oct 2026 | $23.5B |
| 26 Dec 2025 | $19.6B |
| 27 Dec 2024 | $13.3B |
| 29 Dec 2023 | $14.1B |
| 30 Dec 2022 | $17.9B |
| 31 Dec 2021 | $16.2B |
| 25 Dec 2020 | $19.1B |
| 27 Dec 2019 | $19.0B |
| 28 Dec 2018 | $13.3B |
| 29 Dec 2017 | $20.0B |
| 30 Dec 2016 | $18.9B |
| 25 Dec 2015 | $20.3B |
| 26 Dec 2014 | $12.5B |
| 27 Dec 2013 | $8.0B |
| 28 Dec 2012 | $2.1B |
| 30 Dec 2011 | $1.9B |
| 31 Dec 2010 | $2.0B |
| 25 Dec 2009 | $950M |
| 26 Dec 2008 | $360M |
Download Incyte's data as JSON, with the weekly market caps in billions of dollars from 5 Dec 2008.
Workforce
Headcount at 31 Dec 2025
- Employees
- 2,844
As of December 31, 2025, we had 2,844 employees, representing an increase of approximately 9% over our 2,617 employees as of the end of the prior year.
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 30 Sep 2025 to 30 Sep 2026
Directors and officers sold $58.3 million of stock in 37 sales and made no open-market purchases in the 12 months to 30 Sep 2026.
| Date | Person | Value |
|---|---|---|
| 15 Sep 2026Sale | Pablo J. CagnoniPresident, Global Head of R&D | $2.8M |
| 19 Aug 2026Sale | Pablo J. CagnoniPresident, Global Head of R&D | $1.4M |
| 12 Aug 2026Sale | Pablo J. CagnoniPresident, Global Head of R&D | $1.3M |
| 5 Aug 2026Sale | Pablo J. CagnoniPresident, Global Head of R&D | $1.3M |
| 5 Aug 2026Sale | Patrick A. MayesEVP & Chief Scientific Officer | $274K |
| 3 Aug 2026Sale | Patrick A. MayesEVP & Chief Scientific Officer | $729K |
| 31 Jul 2026Sale | Patrick A. MayesEVP & Chief Scientific Officer | $5.0M |
| 31 Jul 2026Sale | Pablo J. CagnoniPresident, Global Head of R&D | $1.9M |
| 16 Jul 2026Sale | Steven H. SteinCMO & Head of Late-Stage Dev | $215K |
| 16 Jul 2026Sale | Mohamed Khairie IssaEVP, Head of U.S. Commercial | $126K |
Showing 10 of 37 trades
Trades by members of Congress and officials
Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.
Trades from 20 Oct 2023 to 20 Oct 2026
2 people disclosed 4 purchases and 3 sales of Incyte stock since October 2023.
| Date | Member or official | Amount |
|---|---|---|
| 4 Sep 2026 | Rohit KhannaHouse, D-CA 路 Bought | $1K to $15K |
| 29 Jan 2026 | Rohit KhannaHouse, D-CA 路 Bought | $1K to $15K |
| 19 May 2025 | Rohit KhannaHouse, D-CA 路 Bought | $1K to $15K |
| 15 May 2025 | Rob BresnahanHouse, R-PA 路 Sold | $1K to $15K |
| 19 Feb 2025 | Rohit KhannaHouse, D-CA 路 Sold | $1K to $15K |
| 17 Jan 2025 | Rohit KhannaHouse, D-CA 路 Bought | $1K to $15K |
| 18 Dec 2024 | Rohit KhannaHouse, D-CA 路 Sold | $1K to $15K |
Not on file: no WARN layoff notices under its own name since October 2023.